Quick Answer
PLIANT THERAPEUTICS, INC. reported R&D Expense of $109.16 million for fiscal year 2025.
PLIANT THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $109.16M | -35.5% |
| 2024 | $169.31M | +32.5% |
| 2023 | $127.80M | +31.8% |
| 2022 | $96.94M | +25.0% |
| 2021 | $77.55M | +17.2% |
| 2020 | $66.19M | +39.8% |
| 2019 | $47.35M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $17.94M | -62.4% | -44.3% |
| June 30, 2025 | $32.20M | -29.4% | -25.9% |
| March 31, 2025 | $43.44M | +16.9% | -9.0% |
| September 30, 2024 | $47.75M | +47.7% | +4.7% |
| June 30, 2024 | $45.62M | +38.2% | +22.8% |
| March 31, 2024 | $37.15M | +26.9% | +14.9% |
| September 30, 2023 | $32.34M | +31.4% | -2.0% |
| June 30, 2023 | $33.00M | +25.3% | +12.7% |
- PLIANT THERAPEUTICS, INC. showed a decrease of -35.5% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, PLIANT THERAPEUTICS, INC.’s r&d expense has grown by 130.5% (from $47.35 million to $109.16 million).
- The most recent figure is from PLIANT THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: